Cargando…
Development of the Myasthenia Gravis (MG) Symptoms PRO: a case study of a patient-centred outcome measure in rare disease
BACKGROUND: Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease, characterised by fluctuating muscle weakness which makes it challenging to assess symptom severity. Mixed methods psychometrics (MMP), which combines evidence from qualitative research and modern psychometrics, is a ve...
Autores principales: | Cleanthous, Sophie, Mork, Ann-Christin, Regnault, Antoine, Cano, Stefan, Kaminski, Henry J., Morel, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556940/ https://www.ncbi.nlm.nih.gov/pubmed/34717694 http://dx.doi.org/10.1186/s13023-021-02064-0 |
Ejemplares similares
-
Measuring Overall Severity of Myasthenia Gravis (MG): Evidence for the Added Value of the MG Symptoms PRO
por: Regnault, Antoine, et al.
Publicado: (2023) -
Correction to: Measuring Overall Severity of Myasthenia Gravis (MG): Evidence for the Added Value of the MG Symptoms PRO
por: Regnault, Antoine, et al.
Publicado: (2023) -
Corticosteroid Treatment-Resistance in Myasthenia Gravis
por: Kaminski, Henry J., et al.
Publicado: (2022) -
Complement Inhibitor Therapy for Myasthenia Gravis
por: Albazli, Khaled, et al.
Publicado: (2020) -
COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)
por: Muppidi, Srikanth, et al.
Publicado: (2020)